President Trump Announces Nationwide Medicaid Drug Pricing Program
President Donald Trump announced that all 50 U.S. states will join a program to implement Most Favored Nation pricing for certain Medicaid drugs, with the aim of lowering their net price to match rates paid in other countries.
Providence New Bedford, RI, September 18, 2026 —
President Donald Trump has announced that all 50 United States are set to participate in a new program focused on implementing Most Favored Nation (MFN) pricing for specific Medicaid drugs. The initiative aims to reduce the net price of these medications by aligning them with rates paid in other developed nations.
The announcement signifies a broad, nationwide effort to address drug costs within the Medicaid program. Most Favored Nation pricing is a policy concept that would typically involve a country or entity seeking to pay no more for a drug than the lowest price paid by other comparable countries. The stated goal of this program is to achieve lower net prices for certain pharmaceuticals purchased through Medicaid.
Further details regarding the specific list of drugs covered by the MFN pricing, the exact mechanism for implementation across all 50 states, and the timeline for when these changes will take effect were not immediately provided. The contractor involved in the program’s administration was also not specified in the announcement.
Story summarized from the original created by FATIMA HUSSEIN Associated Press on www.wpri.com, see more information here.
Media gallery
